Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Operating Leases (2023 - 2025)

Historic Operating Leases for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $4.0 million.

  • Contineum Therapeutics' Operating Leases changed N/A to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year change of. This contributed to the annual value of $4.8 million for FY2024, which is 435092.59% up from last year.
  • Latest data reveals that Contineum Therapeutics reported Operating Leases of $4.0 million as of Q3 2025.
  • Contineum Therapeutics' Operating Leases' 5-year high stood at $4.8 million during Q4 2024, with a 5-year trough of $108000.0 in Q4 2023.
  • Its 3-year average for Operating Leases is $2.6 million, with a median of $4.0 million in 2025.
  • In the last 5 years, Contineum Therapeutics' Operating Leases skyrocketed by 435092.59% in 2024 and then surged by 369115.04% in 2025.
  • Contineum Therapeutics' Operating Leases (Quarter) stood at $108000.0 in 2023, then surged by 4350.93% to $4.8 million in 2024, then decreased by 16.46% to $4.0 million in 2025.
  • Its last three reported values are $4.0 million in Q3 2025, $4.3 million for Q2 2025, and $4.5 million during Q1 2025.